|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Danelli L, Frossi B and Pucillo CE: Mast
cell/MDSC a liaison immunosuppressive for tumor microenvironment.
Oncoimmunology. 4:e10012322015. View Article : Google Scholar :
|
|
3
|
Basith S, Manavalan B, Yoo TH, Kim SG and
Choi S: Roles of Toll-like receptors in cancer: A double-edged
sword for defense and offense. Arch Pharmacal Res. 35:1297–1316.
2012. View Article : Google Scholar
|
|
4
|
Hoyler T, Klose CS, Souabni A,
Turqueti-Neves A, Pfeifer D, Rawlins EL, Voehringer D, Busslinger M
and Diefenbach A: The transcription factor GATA-3 controls cell
fate and maintenance of type 2 innate lymphoid cells. Immunity.
37:634–648. 2012. View Article : Google Scholar :
|
|
5
|
Roediger B and Weninger W: Group 2 innate
lymphoid cells in the regulation of immune responses. Adv Immunol.
125:111–154. 2015. View Article : Google Scholar
|
|
6
|
Halim TY, MacLaren A, Romanish MT, Gold
MJ, McNagny KM and Takei F: Retinoic-acid-receptor-related orphan
nuclear receptor alpha is required for natural helper cell
development and allergic inflammation. Immunity. 37:463–474. 2012.
View Article : Google Scholar
|
|
7
|
Wong SH, Walker JA, Jolin HE, Drynan LF,
Hams E, Camelo A, Barlow JL, Neill DR, Panova V, Koch U, et al:
Transcription factor RORα is critical for nuocyte development. Nat
Immunol. 13:229–236. 2012. View
Article : Google Scholar :
|
|
8
|
Mjösberg JM, Trifari S, Crellin NK, Peters
CP, Van Drunen CM, Piet B, Fokkens WJ, Cupedo T and Spits H: Human
IL-25- and IL-33-responsive type 2 innate lymphoid cells are
defined by expression of CRTH2 and CD161. Nat Immunol.
12:1055–1062. 2011. View
Article : Google Scholar
|
|
9
|
Monticelli LA, Sonnenberg GF, Abt MC,
Alenghat T, Ziegler CG, Doering TA, Angelosanto JM, Laidlaw BJ,
Yang CY, Sathaliyawala T, et al: Innate lymphoid cells promote
lung-tissue homeostasis following infection with influenza virus.
Nat Immunol. 12:1045–1054. 2011. View
Article : Google Scholar :
|
|
10
|
Trikha P and Carson WE III: Signaling
pathways involved in MDSC regulation. Biochim Biophys Acta.
1846:55–65. 2014.
|
|
11
|
Mantovani A: The growing diversity and
spectrum of action of myeloid-derived suppressor cells. Eur J
Immunol. 40:3317–3320. 2010. View Article : Google Scholar
|
|
12
|
Khaled YS, Ammori BJ and Elkord EJ:
Increased levels of granulocytic myeloid-derived suppressor cells
in peripheral blood and tumour tissue of pancreatic cancer
patients. Immunol Res. 2014:8798972014.
|
|
13
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar :
|
|
14
|
Feng PH, Lee KY, Chang YL, Chan YF, Kuo
LW, Lin TY, Chung FT, Kuo CS, Yu CT, Lin SM, et al:
CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and
their clinical relevance in non-small cell lung cancer. Am J Respir
Crit Care Med. 186:1025–1036. 2012. View Article : Google Scholar :
|
|
15
|
Heuvers ME, Muskens F, Bezemer K, Lambers
M, Dingemans AM, Groen HJ, Smit EF, Hoogsteden HC, Hegmans JP and
Aerts JG: Arginase-1 mRNA expression correlates with
myeloid-derived suppressor cell levels in peripheral blood of NSCLC
patients. Lung Cancer. 81:468–474. 2013. View Article : Google Scholar
|
|
16
|
Ortiz ML, Lu L, Ramachandran I and
Gabrilovich DI: Myeloid- derived suppressor cells in the
development of lung cancer. Cancer Immunol Res. 2:50–58. 2014.
View Article : Google Scholar
|
|
17
|
Gabrilovich D: Mechanisms and functional
significance of tumor-induced dendritic-cell defects. Nat Rev
Immunol. 4:941–952. 2004. View
Article : Google Scholar
|
|
18
|
Bronte V, Serafini P, Apolloni E and
Zanovello P: Tumor-induced immune dysfunctions caused by myeloid
suppressor cells. J Immunother. 24:431–446. 2001. View Article : Google Scholar
|
|
19
|
Sinha P, Clements VK and Ostrand-Rosenberg
S: Reduction of myeloid-derived suppressor cells and induction of
M1 macrophages facilitate the rejection of established metastatic
disease. J Immunol. 174:636–645. 2005. View Article : Google Scholar
|
|
20
|
Kusmartsev SA, Li Y and Chen SH: Gr-1+
myeloid cells derived from tumor-bearing mice inhibit primary T
cell activation induced through CD3/CD28 costimulation. J Immunol.
165:779–785. 2000. View Article : Google Scholar
|
|
21
|
Bie Q, Zhang P, Su Z, Zheng D, Ying X, Wu
Y, Yang H, Chen D, Wang S and Xu H: Polarization of ILC2s in
peripheral blood might contribute to immunosuppressive
microenvironment in patients with gastric cancer. J Immunol Res.
2014:9231352014. View Article : Google Scholar :
|
|
22
|
Xu Y, Gao J, Su Z, Dai X, Li Y, Liu Y,
Chen J, Tong J, Zhang Y, Wu C, et al: Down regulation of Hlx
closely related to the decreased expressions of T-bet and Runx3 in
patients with gastric cancer may be associated with a pathological
event leading to the imbalance of Th1/Th2. Clin Dev Immunol.
2012:9498212012. View Article : Google Scholar :
|
|
23
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: Communication from the
International Union Against Cancer and the American Joint Committee
on Cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar
|
|
24
|
Halim TY, Steer CA, Mathä L, Gold MJ,
Martinez-Gonzalez I, McNagny KM, McKenzie AN and Takei F: Group 2
innate lymphoid cells are critical for the initiation of adaptive T
helper 2 cell-mediated allergic lung inflammation. Immunity.
40:425–435. 2014. View Article : Google Scholar :
|
|
25
|
Matthew T, Melissa H, Shinji T, Dawn C,
Kasia G, Kelli B, Marc Q, Martin L, Tina V, Kelli B, et al:
Respiratory syncytial virus infection activates IL-13-producing
group 2 innate lyphoid cells through thymic stromal lymphopoietin.
J Allergy Clin Immunol. 138:814–824.e11. 2016. View Article : Google Scholar :
|
|
26
|
Neill DR, Wong SH, Bellosi A, Flynn RJ,
Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, et al:
Nuocytes represent a new innate effector leukocyte that mediates
type-2 immunity. Nature. 464:1367–1370. 2010. View Article : Google Scholar :
|
|
27
|
Chang YJ, Kim HY, Albacker LA, Baumgarth
N, McKenzie AN, Smith DE, Dekruyff RH and Umetsu DT: Innate
lymphoid cells mediate influenza-induced airway hyperreactivity
independently of adaptive immunity. Nat Immunol. 12:631–638. 2011.
View Article : Google Scholar :
|
|
28
|
Shaw JL, Fakhri S, Citardi MJ, Porter PC,
Corry DB, Kheradmand F, Liu YJ and Luong A: IL-33-responsive innate
lymphoid cells are an important source of IL-13 in chronic
rhinosi-nusitis with nasal polyps. Am J Respir Crit Care Med.
188:432–439. 2013. View Article : Google Scholar
|
|
29
|
Spits H, Artis D, Colonna M, Diefenbach A,
Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius
RE, et al: Innate lymphoid cells-a proposal for uniform
nomenclature. Nat Rev Immunol. 13:145–149. 2013. View Article : Google Scholar
|
|
30
|
Reppert S, Boross I, Koslowski M, Türeci
Ö, Koch S, Lehr HA and Finotto S: A role for T-bet-mediated tumour
immune surveillance in anti-IL-17A treatment of lung cancer. Nat
Commun. 2:6002011. View Article : Google Scholar
|
|
31
|
Wan YY: GATA3: A master of many trades in
immune regulation. Cell. 35:233–242. 2014.
|
|
32
|
Gabitass RF, Annels NE, Stocken DD, Pandha
HA and Middleton GW: Elevated myeloid-derived suppressor cells in
pancreatic, esophageal and gastric cancer are an independent
prognostic factor and are associated with significant elevation of
the Th2 cytokine interleukin-13. Cancer Immonol Immunother.
60:1419–1430. 2011. View Article : Google Scholar
|
|
33
|
Highfill SL, Rodriguez PC, Zhou Q, Goetz
CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody
JS, Munn DH, et al: Bone marrow myeloid-derived suppressor cells
(MDSCs) inhibit graft-versus-host disease (GVHD) via an
arginase-1-dependent mechanism that is upregulated by
interleukin-13. Blood. 116:5738–5747. 2010. View Article : Google Scholar :
|
|
34
|
Van Ginderachter JA, Beschin A, De
Baetselier P and Raes G: Myeloid-derived suppressor cells in
parasitic infections. Eur J Immunol. 40:2976–2985. 2010. View Article : Google Scholar
|
|
35
|
Wu Y, Yan Y, Su Z, Bie Q, Wu J, Wang S, Yu
Y, Ding H, Lu P and Xu H: Enhanced circulating ILC2s accompany by
upregulated MDSCs in patients with asthma. Int J Clin Exp Pathol.
8:3568–3579. 2015.
|
|
36
|
Wolterink RG Klein, Serafini N, Van
Nimwegen M, Vosshenrich CA, de Bruijn MJ, Pereira D Fonseca,
Fernandes H Veiga, Hendriks RW and Di Santo JP: Essential,
dose-dependent role for the transcription factor Gata3 in the
development of IL-5+ and IL-13+ type 2 innate lymphoid cells. Proc
Natl Acad Sci USA. 110:pp. 10240–10245. 2013; View Article : Google Scholar :
|
|
37
|
Bando JK, Nussbaum JC, Liang HE and
Locksley RM: Type 2 innate lymphoid cells constitutively express
arginase-I in the naive and inlamed lung. J Leukoc Biol.
94:877–884. 2013. View Article : Google Scholar :
|
